Open Access
Subscription or Fee Access
Epitope-Based Peptide Vaccine Design Against Nuclear Protein EBNA3C of Epstein-Barr Virus: An Approach to Treat Multiple Sclerosis
Abstract
Almost 95% of the world’s population is affected by the Epstein-Barr virus (EBV); it is an oncogenic virus of herpes virus family. The nuclear protein Epstein-Barr nuclear antigens (EBNA)-3C of EBV are related to multiple sclerosis (MS) which is an inflammatory disease of the nervous system. Regardless of multiple occurrences of infections due to EBV and shortage of licensed antiviral drugs, there is not much advancement on vaccine designed for MS. It is computational approach to identify a multi-epitope vaccine candidate against EBV that could activate significant immune response and let us to determine the novel antigen targets. The sequences of EBV were analysed in silico to identify the most immunogenic protein. The peptide sequence “VHMFMRERQLPQSTG” happened to be the most potential B cell and T cell epitope that had the capability to induce both humoral and cell-mediated immunity. It could interact with 27 human leuckocyte antigens (HLAs) and showed high cumulative coverage ranging from 31.97% to 80.42% as well. An in silico docking detected the binding of epitopes with the HLAs and was found to bind well. The epitope was not an allergen based on the allergenicity calculation. This is a preliminary check and requires confirmation by in vitro and in vivo experiments.
Keywords: vaccinomics, multiple sclerosis (MS), human leuckocyte antigen (HLA), Epstein-Barr nuclear antigens (EBNA)-3C, allergenicity
Cite this Article
Madhumathi S., Aishwarya S., Nandha Devi E., Sagaya Jansi R. Epitope-Based Peptide Vaccine Design Against Nuclear Protein EBNA3C of Epstein-Barr Virus: An Approach to Treat Multiple Sclerosis. Research & Reviews: A Journal of Life Sciences. 2019; 9(1): 62–72p.
Keywords
References
Tselis A, Epstein-Barr virus cause of multiple sclerosis, Curr Opin Rheumatol., Jul;24 (4) 2012, 424-8. doi: 10.1097/BOR.0b013e3283542cf8.
Hassani, Asma, et al. “Epstein-Barr Virus Is Present in the Brain of Most Cases of Multiple Sclerosis and May Engage More than Just B Cells.” Plos One, no. 2, Feb. 2018.
Cepok, S., Zhou, D., Srivastava, R., Nessler, S., Stei, S., Büssow, K., Hemmer, B. Identification of Epstein –Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest., 115(5), 2005, 1352–1360. https://doi.org/10.1172/JCI200523661.1352
Chen, A., Zhao, B., Kieff, E., Aster, J. C., & Wang, F. EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. Journal of Virology, 80(20), 2006, 10139–10150. https://doi.org/10.1128/JVI.00854-06
Sample, J., Young, L., Martin, B., Chatman, T., Kieff, E., Rickinson, a, &Kieff, E., Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. Journal of Virology, 64(9), 1990, 4084–4092.
Pender, Michael P, and Scott R Burrows. “Epstein–Barr Virus and Multiple Sclerosis: Potential Opportunities for Immunotherapy.” Clinical & Translational Immunology 3.10, 2014, e27–. PMC. Web.
Lucas RM, Hughes AM, Lay MJ, et al, lEpstein–Barr virus and multiple sclerosis, Journal of Neurology, Neurosurgery & Psychiatry 2011;82:1142-1148
Emran, A., and Jyoti, T. P., Design of an epitope-based peptide vaccine against spike protein of human coronavirus : an in silico approach, 2014, 1139–1149.
Doytchinova, I. A., and Flower, D. R., VaxiJen : a server for prediction of protective antigens, tumor antigens and subunit vaccines, 7, 1–7. 2007, https://doi.org/10.1186/1471-2105-8-4
Lee, H., Heo, L., Lee, M. S., and Seok, C., GalaxyPepDock : a protein – peptide docking tool based on interaction similarity and energy optimization, 43(May), 2015, 431–435. https://doi.org/10.1093/nar/gkv495
DOI: https://doi.org/10.37591/rrjols.v9i1.1267
Refbacks
- There are currently no refbacks.